JP2003512460A - ２−（４，６−ジメチル−ピリミジン−２−イルオキシ）−３−（２−（３，４−ジメトキシフェニル）エトキシ）−３，３−ジフェニルプロピオン酸−ナトリウム塩及びエンドセリンアンタゴニストとしてのその使用 - Google Patents

２−（４，６−ジメチル−ピリミジン−２−イルオキシ）−３−（２−（３，４−ジメトキシフェニル）エトキシ）−３，３−ジフェニルプロピオン酸−ナトリウム塩及びエンドセリンアンタゴニストとしてのその使用

Info

Publication number
JP2003512460A
JP2003512460A JP2001533121A JP2001533121A JP2003512460A JP 2003512460 A JP2003512460 A JP 2003512460A JP 2001533121 A JP2001533121 A JP 2001533121A JP 2001533121 A JP2001533121 A JP 2001533121A JP 2003512460 A JP2003512460 A JP 2003512460A
Authority
JP
Japan
Prior art keywords
ethoxy
dimethoxyphenyl
yloxy
dimethyl
sodium salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2001533121A
Other languages
English (en)
Japanese (ja)
Inventor
ヤンセン ロルフ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF SE
Original Assignee
BASF SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BASF SE filed Critical BASF SE
Publication of JP2003512460A publication Critical patent/JP2003512460A/ja
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2001533121A 1999-10-27 2000-10-17 ２−（４，６−ジメチル−ピリミジン−２−イルオキシ）−３−（２−（３，４−ジメトキシフェニル）エトキシ）−３，３−ジフェニルプロピオン酸−ナトリウム塩及びエンドセリンアンタゴニストとしてのその使用 Abandoned JP2003512460A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19951671.5 1999-10-27
DE19951671A DE19951671A1 (de) 1999-10-27 1999-10-27 2-(4,6-Dimethyl-pyrimidin-2-yloxy)-3-(2-(3,4-dimethoxyphenyl)ethoxy)-3,3-diphenylpropionssäure-Natriumsalz und seine Verwendung als Endothelinantagonist
PCT/EP2000/010202 WO2001030767A1 (de) 1999-10-27 2000-10-17 2-(4,6-dimethyl-pyrimidin-2-yloxy)-3-(2-(3,4-dimethoxyphenyl)ethoxy)-3,3-diphenylpropionsäure-natriumsalz und seine verwendung als endothelinantagonist

Publications (1)

Publication Number Publication Date
JP2003512460A true JP2003512460A (ja) 2003-04-02

Family

ID=7927001

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001533121A Abandoned JP2003512460A (ja) 1999-10-27 2000-10-17 ２−（４，６−ジメチル−ピリミジン−２−イルオキシ）−３−（２−（３，４−ジメトキシフェニル）エトキシ）−３，３−ジフェニルプロピオン酸−ナトリウム塩及びエンドセリンアンタゴニストとしてのその使用

Country Status (17)

Country Link
EP (1) EP1228047A1 (no)
JP (1) JP2003512460A (no)
KR (1) KR20020047301A (no)
CN (1) CN1384822A (no)
AU (1) AU1272701A (no)
BG (1) BG106700A (no)
BR (1) BR0015112A (no)
CA (1) CA2389012A1 (no)
CZ (1) CZ20021485A3 (no)
DE (1) DE19951671A1 (no)
HU (1) HUP0203476A3 (no)
IL (1) IL149312A0 (no)
MX (1) MXPA02004071A (no)
NO (1) NO20021986L (no)
SK (1) SK5962002A3 (no)
TR (1) TR200201169T2 (no)
WO (1) WO2001030767A1 (no)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1773816T3 (pl) 2004-06-24 2015-06-30 Vertex Pharma Modulatory transporterów posiadających kasetę wiążącą ATP

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19636046A1 (de) * 1996-09-05 1998-03-12 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten

Also Published As

Publication number Publication date
EP1228047A1 (de) 2002-08-07
BR0015112A (pt) 2002-10-29
NO20021986D0 (no) 2002-04-26
NO20021986L (no) 2002-04-26
BG106700A (en) 2003-02-28
WO2001030767A1 (de) 2001-05-03
MXPA02004071A (es) 2002-10-11
SK5962002A3 (en) 2002-09-10
DE19951671A1 (de) 2001-05-03
HUP0203476A2 (en) 2003-05-28
TR200201169T2 (tr) 2002-09-23
IL149312A0 (en) 2002-11-10
KR20020047301A (ko) 2002-06-21
CA2389012A1 (en) 2001-05-03
HUP0203476A3 (en) 2003-07-28
CN1384822A (zh) 2002-12-11
CZ20021485A3 (cs) 2003-06-18
AU1272701A (en) 2001-05-08

Similar Documents

Publication Publication Date Title
TW397825B (en) Aroyl-piperidine derivatives
JP2021504310A (ja) 血漿カリクレイン阻害剤及びその塩の固体形態
JP2000504315A (ja) ブラジキニン受容体親和性を有する新規ｎ―（アリールスルホニル）アミノ酸誘導体
CZ49399A3 (cs) Derivát arylalkanoylpyridazinu, způsob jeho přípravy a farmaceutický prostředek, který ho obsahuje
JPH11505236A (ja) フェニルジヒドロベンゾフラン
JP2001509810A (ja) Ｍｍｐインヒビターとしてのビス−スルホンアミドヒドロキサム酸
JP2003137866A (ja) フェニレンジアミン誘導体
TW200300344A (en) Triazolo[4,3-a]pyrido[2,3-d]pyrimidin-5-one derivatives, compositions containing them, method of preparation and use
JP2001513767A (ja) メタロプロテアーゼ阻害剤としての逆ヒドロキサメート誘導体
JPS636058B2 (no)
WO2006018955A1 (ja) イソインドール誘導体の製造方法
JP3539926B2 (ja) 抗ウイルス性ピリミジンジオン誘導体及びそれらの製造方法
CN101006087B (zh) 作为p38MAP激酶抑制剂的三唑并吡啶基硫烷基衍生物
JP6275644B2 (ja) Ｎ−［２−（｛２−［（２Ｓ）−２−シアノピロリジン−１−イル］−２−オキソエチル｝アミノ）−２−メチルプロピル］−２−メチルピラゾロ［１，５−ａ］ピリミジン−６−カルボキサミドの結晶
CA2403264A1 (en) Chiral fluoroquinolizinone arginine salt forms
AU765213B2 (en) Tetrahydroindazole derivatives as ligands for gaba-a alpha 5 receptors
JP3199736B2 (ja) アミノアルキル置換された２−アミノ−５−メルカプトチアジアゾール、その製造及び使用
JP2003512460A (ja) ２−（４，６−ジメチル−ピリミジン−２−イルオキシ）−３−（２−（３，４−ジメトキシフェニル）エトキシ）−３，３−ジフェニルプロピオン酸−ナトリウム塩及びエンドセリンアンタゴニストとしてのその使用
EP0703915B1 (en) Xamoneline tartrate
JP2003502425A (ja) Ｎｋ−１受容体アンタゴニストとしての（２−ベンズヒドリル−１−アザビシクロ［２．２．２］オクト−３−イル）−（５−イソプロピル−２−メトキシベンジル）−アンモニウムクロリドの結晶多形
JP2003508517A (ja) キノロンカルボン酸誘導体の製造に関する中間体
GB2171997A (en) 4-Amino-6,7-dimethoxy-2-Piperazin-1-ylquinazoline derivatives
JP3116256B2 (ja) （チオ）ウレア誘導体
JPH0662547B2 (ja) グリシン誘導体
US11542279B2 (en) Solid forms of ceftolozane and processes for preparing

Legal Events

Date Code Title Description
A762 Written abandonment of application

Free format text: JAPANESE INTERMEDIATE CODE: A762

Effective date: 20050728